NCT07262944 EOI Block in Otoplasty With Rib Cartilage Graft
| NCT ID | NCT07262944 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Postoperative Pain, Acute |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-12-01 |
| Primary Completion | 2028-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-12-01 with a primary completion date of 2028-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial aims to evaluate the effect of ultrasound-guided external oblique intercostal (EOI) fascial plane block on postoperative pain control and recovery in pediatric patients undergoing otoplasty with rib cartilage graft under general anesthesia. Participants aged 13 to 18 years will be randomly assigned to receive either EOI block with 0.2% ropivacaine or no block. Primary outcome is total opioid consumption within 24 hours after surgery. Secondary outcomes include NRS pain scores, incentive spirometry performance, incidence of atelectasis, and patient satisfaction.
Eligibility Criteria
Inclusion Criteria: * \- Pediatric patients aged 13 to 18 years undergoing otoplasty with rib cartilage graft under general anesthesia at Seoul National University Children's Hospital * Written informed consent obtained from parent or legal guardian, and assent from the patient Exclusion Criteria: * Unstable vital signs before surgery (heart rate \<50 or \>150 beats/min, systolic blood pressure \<80 mmHg or \>160 mmHg) * Known hypersensitivity to ropivacaine or other amide-type local anesthetics * Massive bleeding or shock * Local infection at the injection site * Sepsis * History of allergy to opioid medications * Severe renal dysfunction (creatinine \>3.0 mg/dL) * Severe hepatic dysfunction (AST or ALT \>120 U/L) * Any condition that, in the investigator's opinion, makes the subject unsuitable for study participation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07262944 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, up to 18 Years, studying Postoperative Pain, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07262944 currently recruiting?
Yes, NCT07262944 is actively recruiting participants. Contact the research team at jb4001@snu.ac.kr for enrollment information.
Where is the NCT07262944 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07262944 clinical trial?
NCT07262944 is sponsored by Seoul National University Hospital. The trial plans to enroll 60 participants.